• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长链非编码RNA ADAMTS9-AS2是一种预后生物标志物，与肺腺癌中的免疫浸润相关。

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma.

作者信息

Lin Zhichao, Huang Wenhai, Yi Yongsheng, Li Dongbing, Xie Zehua, Li Zumei, Ye Min

机构信息

Department of Thoracic Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, Guangdong, People's Republic of China.

MyGene Diagnostics Co., Ltd., Guangzhou, 510000, Guangdong, People's Republic of China.

出版信息

Int J Gen Med. 2021 Nov 20;14:8541-8555. doi: 10.2147/IJGM.S340683. eCollection 2021.

DOI:10.2147/IJGM.S340683
PMID:34849000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8626860/
Abstract

BACKGROUND

The role of long noncoding RNA (LncRNA) ADAMTS9 antisense RNA 2 (ADAMTS9-AS2) is unclear in lung adenocarcinoma (LUAD). The aim of this study was to explore the relationship between ADAMTS9-AS2 and LUAD, based on The Cancer Genome Atlas (TCGA) database and bioinformatics analysis.

METHODS

Various statistical methods, Kaplan-Meier method, Cox regression analysis, GSEA, and immune infiltration analysis were used to evaluate the relationship between clinical features and ADAMTS9-AS2 expression, prognostic factors, and the significant involvement of ADAMTS9-AS2 in function.

RESULTS

In LUAD patients, low expression of ADAMTS9-AS2 was associated with N stage (P=0.011), gender (P=0.002), number of packs smoked (P=0.024) and smoker (P<0.001). Low ADAMTS9-AS2 expression predicted a poorer overall survival (OS) (HR: 0.68; 95% CI: 0.51-0.91; P=0.01). And ADAMTS9-AS2 expression (HR: 0.626; 95% CI: 0.397-0.986; P=0.043) was independently correlated with OS in LUAD patients. Unwinding of DNA, extrinsic pathway, polo-like kinase-mediated events, cori cycle, MCM pathway, proteasome pathway, lagging strand synthesis and PCNA-dependent long patch base excision repair were differentially enriched in ADAMTS9-AS2 high expression phenotype. ADAMTS9-AS2 expression was correlated with certain immune infiltrating cells.

CONCLUSION

In LUAD patients, ADAMTS9-AS2 expression was significantly associated with poor survival and immune infiltration. ADAMTS9-AS2 may be a promising biomarker of prognosis and response to immunotherapy for LUAD.

摘要

背景

长链非编码RNA（LncRNA）ADAMTS9反义RNA 2（ADAMTS9-AS2）在肺腺癌（LUAD）中的作用尚不清楚。本研究旨在基于癌症基因组图谱（TCGA）数据库和生物信息学分析，探讨ADAMTS9-AS2与LUAD之间的关系。

方法

采用多种统计方法、Kaplan-Meier法、Cox回归分析、基因集富集分析（GSEA）和免疫浸润分析，评估临床特征与ADAMTS9-AS2表达、预后因素以及ADAMTS9-AS2在功能上的显著参与之间的关系。

结果

在LUAD患者中，ADAMTS9-AS2低表达与N分期（P=0.011）、性别（P=0.002）、吸烟包年数（P=0.024）和吸烟状态（P<0.001）相关。ADAMTS9-AS2低表达预示总体生存期（OS）较差（HR：0.68；95%CI：0.51-0.91；P=0.01）。并且ADAMTS9-AS2表达（HR：0.626；95%CI：0.397-0.986；P=0.043）与LUAD患者的OS独立相关。DNA解旋、外源性途径、polo样激酶介导的事件、科里循环、微小染色体维持蛋白（MCM）途径、蛋白酶体途径、滞后链合成和增殖细胞核抗原（PCNA）依赖性长片段碱基切除修复在ADAMTS9-AS2高表达表型中差异富集。ADAMTS9-AS2表达与某些免疫浸润细胞相关。

结论

在LUAD患者中，ADAMTS9-AS2表达与不良生存和免疫浸润显著相关。ADAMTS9-AS2可能是LUAD预后和免疫治疗反应的一个有前景的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/d960a5a75b46/IJGM-14-8541-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/5f21695d116b/IJGM-14-8541-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/417be78c947e/IJGM-14-8541-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/4f8b5bdc53e9/IJGM-14-8541-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/6e3c6776ed25/IJGM-14-8541-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/9b089cc1595c/IJGM-14-8541-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/f0f79dc81c1e/IJGM-14-8541-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/85edbb96d8db/IJGM-14-8541-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/663e11a6ff87/IJGM-14-8541-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/d960a5a75b46/IJGM-14-8541-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/5f21695d116b/IJGM-14-8541-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/417be78c947e/IJGM-14-8541-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/4f8b5bdc53e9/IJGM-14-8541-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/6e3c6776ed25/IJGM-14-8541-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/9b089cc1595c/IJGM-14-8541-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/f0f79dc81c1e/IJGM-14-8541-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/85edbb96d8db/IJGM-14-8541-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/663e11a6ff87/IJGM-14-8541-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ad/8626860/d960a5a75b46/IJGM-14-8541-g0009.jpg

相似文献

1
LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma.长链非编码RNA ADAMTS9-AS2是一种预后生物标志物，与肺腺癌中的免疫浸润相关。
Int J Gen Med. 2021 Nov 20;14:8541-8555. doi: 10.2147/IJGM.S340683. eCollection 2021.
2
Bioinformatics Analysis and Functional Verification of ADAMTS9-AS1/AS2 in Lung Adenocarcinoma.肺腺癌中ADAMTS9-AS1/AS2的生物信息学分析与功能验证
Front Oncol. 2021 Jul 29;11:681777. doi: 10.3389/fonc.2021.681777. eCollection 2021.
3
[Overexpression of the long non-coding RNA ADAMTS9-AS2 suppresses colorectal cancer proliferation and metastasis].长链非编码RNA ADAMTS9-AS2的过表达抑制结直肠癌的增殖和转移
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Jul 28;44(7):741-748. doi: 10.11817/j.issn.1672-7347.2019.190142.
4
Decreased Expression of a Novel lncRNA FAM181A-AS1 is Associated with Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma.新型长链非编码RNA FAM181A-AS1表达降低与肺腺癌预后不良及免疫浸润相关。
Pharmgenomics Pers Med. 2022 Dec 2;15:985-998. doi: 10.2147/PGPM.S384901. eCollection 2022.
5
A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells.一种新的肿瘤抑制性长链非编码RNA ADAMTS9-AS2受DNA甲基转移酶1调控并抑制胶质瘤细胞迁移。
Tumour Biol. 2014 Aug;35(8):7935-44. doi: 10.1007/s13277-014-1949-2. Epub 2014 May 15.
6
Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.预测涉及人肺腺癌进展的失调竞争内源性 RNA 特征。
Cancer Biomark. 2020;29(3):399-416. doi: 10.3233/CBM-200133.
7
MiR-195-3p is a Novel Prognostic Biomarker Associated with Immune Infiltrates of Lung Adenocarcinoma.MiR-195-3p是一种与肺腺癌免疫浸润相关的新型预后生物标志物。
Int J Gen Med. 2022 Jan 6;15:191-203. doi: 10.2147/IJGM.S350340. eCollection 2022.
8
The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population.循环 lncRNA ADAMTS9-AS2 肿瘤标志物在埃及人群中非小细胞肺癌中的诊断意义。
J Gene Med. 2021 Dec;23(12):e3381. doi: 10.1002/jgm.3381. Epub 2021 Aug 24.
9
plays a significant prognostic role in lung adenocarcinoma and is associated with tumor immunity based on bioinformatics analysis.基于生物信息学分析，其在肺腺癌中发挥着重要的预后作用，并与肿瘤免疫相关。
Ann Transl Med. 2022 May;10(9):519. doi: 10.21037/atm-22-1430.
10
A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.一种新型坏死性凋亡相关lncRNA特征预测肺腺癌预后
Front Genet. 2022 Mar 17;13:862741. doi: 10.3389/fgene.2022.862741. eCollection 2022.

引用本文的文献

1
Association between SOX gene family expression, DNA methylation, and miRNA regulation in lung adenocarcinoma progression.肺腺癌进展过程中SOX基因家族表达、DNA甲基化与miRNA调控之间的关联
Discov Oncol. 2025 Feb 15;16(1):188. doi: 10.1007/s12672-025-01892-x.
2
ZNF165: A Pan-Cancer Biomarker with Prognostic and Therapeutic Potential.锌指蛋白165：一种具有预后和治疗潜力的泛癌生物标志物。
Protein Pept Lett. 2025;32(3):206-223. doi: 10.2174/0109298665351592250106062250.
3
ZP3 Expression in Pancreatic Adenocarcinoma: Its Implications for the Prognosis and Therapy.

本文引用的文献

1
ADAMTS9-AS2: a potential diagnostic and prognostic hallmark in prostate cancer.ADAMTS9反义RNA2：前列腺癌潜在的诊断和预后标志物
J BUON. 2021 Jul-Aug;26(4):1623-1627.
2
The Immune-Related Gene ELF3 is a Novel Biomarker for the Prognosis of Ovarian Cancer.免疫相关基因ELF3是卵巢癌预后的新型生物标志物。
Int J Gen Med. 2021 Sep 10;14:5537-5548. doi: 10.2147/IJGM.S332320. eCollection 2021.
3
Bioinformatics Analysis and Functional Verification of ADAMTS9-AS1/AS2 in Lung Adenocarcinoma.肺腺癌中ADAMTS9-AS1/AS2的生物信息学分析与功能验证
胰腺癌中ZP3的表达：其对预后和治疗的意义
Protein Pept Lett. 2025;32(2):124-138. doi: 10.2174/0109298665350171241204153202.
4
Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer.HEPACAM2作为结直肠癌潜在预后生物标志物和免疫治疗靶点的综合分析与实验验证
Curr Gene Ther. 2024 Nov 1. doi: 10.2174/0115665232325395241018103006.
5
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.RPL22L1 是肺腺癌预后和免疫浸润的新型生物标志物，通过抑制 MDM2/P53 信号通路促进 LUAD 细胞的生长和转移。
Aging (Albany NY). 2024 Aug 28;16(17):12392-12413. doi: 10.18632/aging.206096.
6
The Role of TGFBR3 in the Development of Lung Cancer.TGFBR3 在肺癌发展中的作用。
Protein Pept Lett. 2024;31(7):491-503. doi: 10.2174/0109298665315841240731060636.
7
ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.ADAMTSL2 是结直肠癌潜在的预后生物标志物和免疫治疗靶点：生物信息学分析和实验验证。
PLoS One. 2024 May 30;19(5):e0303909. doi: 10.1371/journal.pone.0303909. eCollection 2024.
8
Four centrosome-related genes to predict the prognosis and drug sensitivity of patients with colon cancer.四个与中心体相关的基因用于预测结肠癌患者的预后和药物敏感性。
World J Gastrointest Oncol. 2024 May 15;16(5):1908-1924. doi: 10.4251/wjgo.v16.i5.1908.
9
Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma.卵巢高级别浆液性癌中特异性下调的长链非编码RNA的鉴定
Reprod Med Biol. 2024 Apr 3;23(1):e12572. doi: 10.1002/rmb2.12572. eCollection 2024 Jan-Dec.
10
ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.ZNF695，一种潜在的预后生物标志物，与宫颈鳞癌和宫颈内膜腺癌中的免疫浸润相关：生物信息学分析和实验验证。
Curr Gene Ther. 2024;24(5):441-452. doi: 10.2174/0115665232285216240228071244.
Front Oncol. 2021 Jul 29;11:681777. doi: 10.3389/fonc.2021.681777. eCollection 2021.
4
LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.长链非编码 RNA ELF3-AS1 是肝癌的预后生物标志物，并与免疫浸润相关。
Can J Gastroenterol Hepatol. 2021 Jul 9;2021:8323487. doi: 10.1155/2021/8323487. eCollection 2021.
5
The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population.循环 lncRNA ADAMTS9-AS2 肿瘤标志物在埃及人群中非小细胞肺癌中的诊断意义。
J Gene Med. 2021 Dec;23(12):e3381. doi: 10.1002/jgm.3381. Epub 2021 Aug 24.
6
Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion.长链非编码RNA ADAMTS9-AS2抑制肝癌细胞的增殖、迁移和侵袭。
Exp Ther Med. 2021 Jun;21(6):559. doi: 10.3892/etm.2021.9991. Epub 2021 Mar 26.
7
Long-Chain Noncoding RNA ADAMTS9-AS2 Regulates Proliferation, Migration, and Apoptosis in Bladder Cancer Cells Through Regulating miR-182-5p.长链非编码 RNA ADAMTS9-AS2 通过调控 miR-182-5p 调节膀胱癌细胞的增殖、迁移和凋亡。
J Interferon Cytokine Res. 2021 Feb;41(2):60-71. doi: 10.1089/jir.2020.0137.
8
Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma.新型长链非编码 RNA UPLA1 介导肺腺癌的发生发展和预后。
Cell Death Dis. 2020 Nov 21;11(11):999. doi: 10.1038/s41419-020-03198-y.
9
Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.全面分析 TPX2 相关 ceRNA 网络作为肺腺癌的预后生物标志物。
Int J Med Sci. 2020 Sep 1;17(16):2427-2439. doi: 10.7150/ijms.49053. eCollection 2020.
10
and expression and association with the prognosis in esophageal squamous cell carcinoma.并探讨其在食管鳞癌中的表达及与预后的关系。
Biomark Med. 2020 Oct;14(15):1415-1426. doi: 10.2217/bmm-2020-0432. Epub 2020 Sep 7.